|
시장보고서
상품코드
2052457
다발성 경화증 치료제 시장 : 약물 종류별, 투여 경로별, 유통 채널별, 지역별Multiple Sclerosis Therapeutics Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
다발성 경화증 치료제 시장은 2026년에 327억 7,000만 달러로 추정되며, 2033년까지 443억 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 4.4%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 327억 7,000만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 4.40% | 2033년 시장 규모 예측: | 443억 달러 |
다발성 경화증(MS)은 중추신경계(CNS)에 영향을 미치는 만성 자가면역질환입니다. 이는 면역계가 중추신경계의 신경섬유를 덮고 있는 보호막인 미엘린을 공격하여 발생합니다. 이 손상은 뇌와 신체의 다른 부위 사이의 정보 전달을 방해합니다. 증상은 중추신경계 병변의 수와 부위에 따라 경증부터 중증까지 다양하게 나타납니다. 일반적인 증상으로는 피로감, 사지의 약화 및 마비, 협응력 및 평형감각 저하, 시각 장애, 인지 기능 장애 등이 있습니다. 현재 다발성 경화증의 근본적인 치료법은 확립되어 있지 않지만, 인터페론, 글라티라머 아세테이트, 단클론항체, 코르티코스테로이드 등의 약물을 통해 증상을 관리하고 진행을 늦출 수 있습니다.
시장 역학
세계 다발성 경화증 치료제 시장의 성장은 선진국과 개발도상국의 다발성 경화증 유병률 증가, 고령 인구 증가, 다발성 경화증에 대한 신규 및 혁신적 치료제의 견고한 파이프라인, 의료 비용의 급격한 증가, 의료비 환급 제도 가용성 등의 요인에 의해 주도되고 있습니다. 그러나 다발성 경화증 치료제에 따른 높은 비용이 시장 성장을 저해할 수 있습니다. 다발성 경화증 치료에서 맞춤형 의료의 등장, 병용요법, 정맥주사, 경구용 약물의 채택 확대는 시장 성장의 기회를 가져올 수 있습니다.
본 조사의 주요 특징
- 이 보고서는 각 부문의 잠재적 수익기회를 파악하고, 이 시장의 매력적인 투자 제안 매트릭스를 설명합니다.
- 또한 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업의 경쟁 전략에 대한 중요한 인사이트를 제공합니다.
- 본 보고서는 세계 다발성 경화증 치료제 시장의 주요 기업 프로파일을 다음과 같은 매개변수(기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 재무 성과, 전략)를 기반으로 작성되었습니다.
- 이 보고서의 내용을 통해 기업의 마케팅 담당자와 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대, 마케팅 전략에 대한 정보에 입각한 의사결정을 내릴 수 있을 것입니다.
- 세계 다발성 경화증 치료제 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입자, 재무 분석가 등 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계 다발성 경화증 치료제 시장 분석에 사용되는 다양한 전략 매트릭스를 활용하여 의사결정을 원활하게 내릴 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 다발성 경화증 치료제 시장 : 약물 종류별, 2021-2033년
제5장 세계의 다발성 경화증 치료제 시장 : 투여 경로별, 2021-2033년
제6장 세계의 다발성 경화증 치료제 시장 : 유통 채널별, 2021-2033년
제7장 세계의 다발성 경화증 치료제 시장 : 지역별, 2021-2033년
제8장 경쟁 구도
제9장 애널리스트의 제안
제10장 참고문헌 및 조사 방법
KSMMultiple Sclerosis Therapeutics Market is estimated to be valued at USD 32.77 Bn in 2026 and is expected to reach USD 44.30 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.4% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 32.77 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 4.40% | 2033 Value Projection: | USD 44.30 Bn |
Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.
Market Dynamics
Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.
Key features of the study
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up gradation, market expansion, and marketing tactics.
- Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market.
Market Segmentation
- By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
- Beta Interferon
- Corticosteroids
- Monoclonal Antibodies
- Antineoplastic Agent
- Others
- By Route of Administration Insights (Revenue, USD Bn, 2021 - 2033)
- Oral
- Injection
- Others
- By Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Biogen Inc.
- Novartis AG
- Merck KGaA
- Sanofi S. A.
- Acorda Therapeutics, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Bristol-Myers Squibb Company
- Bayer AG
- Hoffmann-La Roche AG
- Viatris Inc. (Mylan NV)
- Johnson & Johnson
- EMD Serono, Inc.
- TG Therapeutics, Inc.
- Genentech, Inc.
- Celgene Corporation
- AbbVie Inc.
- Amgen Inc.
- UCB S.A.
- Sandoz (a Novartis division)
- Ipsen S.A.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Multiple Sclerosis Therapeutics Market, By Drug Class
- Global Multiple Sclerosis Therapeutics Market, By Route of Administration
- Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
- Global Multiple Sclerosis Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Beta Interferon
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Corticosteroids
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Antineoplastic Agent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2021 - 2033, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2033, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Drug Class, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Route of Administration, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- Biogen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S. A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Acorda Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceuticals Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol-Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Viatris Inc. (Mylan NV)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- EMD Serono, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- TG Therapeutics, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Genentech, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Celgene Corporation
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- UCB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sandoz (a Novartis division)
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ipsen S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
